Once again, we have surveyed C-level executives from the pharma and BioTech sector for the Life Sciences Executives Flash Report to gain insights and to draw a current picture of the industry.
Despite concerns about Europe's competitiveness, the industry remains optimistic about profitable growth in the coming years, focusing on cost efficiency.
Top-line growth is expected primarily through volume increases of established products and brands, as well as acquisitions. Mergers & Acquisitions (M&A) are seen as the preferred growth strategy, while geographical expansion is less relevant due to geopolitical risks. The study highlights the importance of AI innovations, cost control, and global regulatory harmonization.
Discover the latest trends and strategies in the life sciences industry in our comprehensive report.
.
